96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination

BACKGROUND: RSV infections are frequent and can lead to respiratory complications in older adults (OA). However, there is no licensed RSV vaccine yet. Here we present immunogenicity results up to month (M) 6 after vaccination with the RSVPreF3 OA. METHODS: In this phase 3 multi-country ongoing study...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarz, Tino F, Hwang, Shinn-Jang, Ylisastigui, Pedro P, Liu, Chiu-Shong, Takazawa, Kenji, Yono, Makoto, Ervin, John E, Andrews, Charles, Fogarty, Charles, Eckermann, Tamara, Collete, Delphine, de Heusch, Magali, Schrevel, Nathalie De, Salaun, Bruno, Lievens, Marc, Maréchal, Céline, Nakanwagi, Phoebe, Hulstrøm, Veronica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751606/
http://dx.doi.org/10.1093/ofid/ofac492.174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751606/
http://dx.doi.org/10.1093/ofid/ofac492.174

Ejemplares similares